One-Liner
A consumer tool helping patients submit structured adverse drug event reports to the FDA's FAERS reporting system.
AI Thinking Process
Consumer FAERS Adverse Event Builder: AI interviews patient in plain language, extracts structured FAERS fields, fills submission, generates audit trail. Capability change: domain-specific medical language now tractable for consumer-facing tool.
G004 structural adoption barrier: adverse event survivor focuses on recovery, not activism. No monetary benefit. G008 Frequency Trap: lifetime event, no subscription. Adoption motivation weak even when form barrier removed.
G023 Pivot: plaintiffs' law firms handling ~50K drug-injury cases per year. $200-500/case B2B pricing. 30-150 high-volume target firms.
KILLED: consumer pivot — no financial incentive, weak motivation. B2B pivot — thin TAM ($1-5M ceiling), absorbed by CaseGlide/Litify/Filevine as one-sprint feature.
Kill Reason
Patients experiencing adverse events focus on recovery, not consumer activism — there is no monetary benefit from filing a FAERS report. The product is also a lifetime event for most patients, with no subscription model viable. B2B pivot (plaintiffs' law firms) fails on thin addressable market ($1-5M ceiling) and feature absorption by legal case management vendors (CaseGlide, Litify, Filevine) in one sprint.
Risk Analysis
Risk analysis available for latest engine ideas.
What do you think?
Related ideas you can explore free:
killed: Open-source middleware (HAMi) already provides heterogeneous AI computing virtualization for free. Proprietary play is squeezed between free open-source and vertically integrated hardware vendor ecosystem.
killed: 5+ funded competitors including Cast AI ($1B valuation), OneChronos (backed by Nobel laureate), Akash Network (decentralized, 80% cheaper), Argentum AI (blockchain-settled). Market is claimed with massive capital.
killed: Template epidemic (G003) + industry-pain-form death pattern (G005) fire simultaneously. 13+ existing compliance tools. A prompt could do 80% of this.